258 related articles for article (PubMed ID: 26068448)
1. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
[TBL] [Abstract][Full Text] [Related]
3. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
4. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
Deichmann M; Benner A; Waldmann V; Bock M; Jäckel A; Näher H
J Exp Clin Cancer Res; 2000 Sep; 19(3):301-7. PubMed ID: 11144523
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
7. DJ-1: a promising marker in metastatic uveal melanoma.
Chen LL; Tian JJ; Su L; Jing Y; Zhang SC; Zhang HX; Wang XQ; Zhu CB
J Cancer Res Clin Oncol; 2015 Feb; 141(2):315-21. PubMed ID: 25129821
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
9. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients.
Klingenstein A; Haritoglou I; Schaumberger MM; Nentwich MM; Hein R; Schaller UC
Melanoma Res; 2011 Aug; 21(4):352-6. PubMed ID: 21540751
[TBL] [Abstract][Full Text] [Related]
10. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
11. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
12. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.
Maier T; Laubender RP; Sturm RA; Klingenstein A; Korting HC; Ruzicka T; Berking C
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1084-91. PubMed ID: 21838826
[TBL] [Abstract][Full Text] [Related]
14. Soluble c-Met protein as a susceptible biomarker for gastric cancer risk: A nested case-control study within the Korean Multicenter Cancer Cohort.
Yang JJ; Yang JH; Kim J; Ma SH; Cho LY; Ko KP; Shin A; Choi BY; Kim HJ; Han DS; Eun CS; Song KS; Kim YS; Chang SH; Shin HR; Kang D; Yoo KY; Park SK
Int J Cancer; 2013 May; 132(9):2148-56. PubMed ID: 23001699
[TBL] [Abstract][Full Text] [Related]
15. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker.
Barak V; Frenkel S; Valyi-Nagy K; Leach L; Apushkin MA; Lin AY; Kalickman I; Baumann NA; Pe'er J; Maniotis AJ; Folberg R
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4399-402. PubMed ID: 17898257
[TBL] [Abstract][Full Text] [Related]
16. c-MET expression in primary and liver metastases in uveal melanoma.
Gardner FP; Serie DJ; Salomao DR; Wu KJ; Markovic SN; Pulido JS; Joseph RW
Melanoma Res; 2014 Dec; 24(6):617-20. PubMed ID: 25211165
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
18. ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion.
Gangemi R; Amaro A; Gino A; Barisione G; Fabbi M; Pfeffer U; Brizzolara A; Queirolo P; Salvi S; Boccardo S; Gualco M; Spagnolo F; Jager MJ; Mosci C; Rossello A; Ferrini S
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1138-48. PubMed ID: 25124714
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of S-100-beta serum concentration in patients with uveal melanoma.
Missotten GS; Tang NE; Korse CM; Hurks HM; de Wolff-Rouendaal D; Keunen JE; Jager MJ; Bonfrer JM
Arch Ophthalmol; 2003 Aug; 121(8):1117-9. PubMed ID: 12912688
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]